Maha H. A. Hussain, MD, FASCO, FACP, outlines the design and key findings from a phase 2 trial of abiraterone plus olaparib vs each agent alone in mCRPC.
Maha H. A. Hussain, MD, FASCO, FACP
Advertisement
Articles by Maha H. A. Hussain, MD, FASCO, FACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
The ArteraAI Prostate Test: What It Is and How It Works
2
HHS requests testosterone therapy label updates, citing new safety data
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
Unmet needs and emerging solutions in MRI-guided prostate cancer care
5